A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs OVX-836 (Primary) ; OVX-836 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors OSIVAX
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 10 Jul 2019 According to an OSIVAX media release, initial results are expected in the second half of 2019.
- 28 Mar 2019 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.